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Abstract
Background: Pilot and feasibility work is conducted to evaluate the operational feasibility and acceptability of the
intervention itself and the feasibility and acceptability of a trials’ protocol design. The Cardiac Rehabilitation In
Bowel cancer (CRIB) study was a pilot randomised controlled trial (RCT) of cardiac rehabilitation versus usual care
(no rehabilitation) for post-surgical colorectal cancer patients. A key aim of the pilot trial was to test the feasibility
and acceptability of the protocol design.
Methods: A pilot RCT with embedded qualitative work was conducted in three sites. Participants were randomly
allocated to cardiac rehabilitation or usual care groups. Outcomes used to assess the feasibility and acceptability of
key trial parameters were screening, eligibility, consent, randomisation, adverse events, retention, completion,
missing data, and intervention adherence rates. Colorectal patients’ and clinicians’ perceptions and experiences of
the main trial procedures were explored by interview.
Results: Quantitative study. Three sites were involved. Screening, eligibility, consent, and retention rates were 79 %
(156/198), 67 % (133/198), 31 % (41/133), and 93 % (38/41), respectively. Questionnaire completion rates were 97.
5 % (40/41), 75 % (31/41), and 61 % (25/41) at baseline, follow-up 1, and follow-up 2, respectively. Sixty-nine
percent (40) of accelerometer datasets were collected from participants; 31 % (20) were removed for not meeting
wear-time validation.
Qualitative study: Thirty-eight patients and eight clinicians participated. Key themes were benefits for people with
colorectal cancer attending cardiac rehabilitation, barriers for people with colorectal cancer attending cardiac
rehabilitation, generic versus disease-specific rehabilitation, key concerns about including people with cancer in
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cardiac rehabilitation, and barriers to involvement in a study about cardiac rehabilitation.
Conclusions: The study highlights where threats to internal and external validity are likely to arise in any future studies of
similar structured physical activity interventions for colorectal cancer patients using similar methods being conducted in
similar contexts. This study shows that there is likely to be potential recruitment bias and potential imprecision due to
sub-optimal completion of outcome measures, missing data, and sub-optimal intervention adherence. Hence, strategies
to manage these risks should be developed to stack the odds in favour of conducting successful future trials.
Trial registration: ISRCTN63510637
Keywords: Pilot, Feasibility, Acceptability, Cardiac rehabilitation, Colorectal cancer, Physical activity
Background
Randomised controlled trials (RCTs) are used to assess
the benefits and potential harm of new interventions in
health care. Pilot and feasibility work is conducted to
evaluate the operational feasibility and acceptability of
the intervention itself and the feasibility and acceptabil-
ity of a trials’ protocol design. There is little point in
running large-scale (and thereby presumably expensive)
trials of interventions—even those suggesting promise of
effect—if these interventions are unlikely to ever see the
light of day and be implemented in practice. Likewise, if
trial procedures prove to be unfeasible then results
about clinical- and cost-effectiveness will not be valid,
thereby making it difficult for policy makers, service
commissioners, and clinicians to decide whether to
adopt an intervention. Conducting pilot studies to iron
out methodological bias and imprecision in advance of a
large-scale trial is critical if that larger trial is to become
part of an evidence-base that is then used for recom-
mending policy and changing practice.
Research funding bodies and trial methodologists
recommend pilot and feasibility studies [1, 2]. If the
research is novel, there are usually uncertainties regard-
ing key trial parameters such as recruitment and loss to
follow-up. These parameters are critical to ensuring that
a trial is sufficiently powered to determine differences in
outcomes between experimental versus control groups
and to reduce risk of bias. Findings from feasibility and
pilot work about trial parameters can be used to opti-
mise the design and conduct of any subsequent large-
scale trial and to judge whether it is even appropriate
and ethical to proceed to such a trial.
Feasibility and pilot work may not always be necessary
if similar studies exist. Trialists can assess the likelihood
of success of their intervention and trial procedures by
examining these studies. At the time of developing our
proposal, we were aware of 12 on-going or published
studies of structured physical activity interventions for
people with colorectal cancer (CRC) [3–14]. These trials
varied by type of intervention (e.g., exercise classes,
home-based exercise prescription, counselling) and
clinical endpoints (e.g., biomarkers, physical activity,
quality of life). Moreover, most were small studies
thereby making it difficult to draw inferences about the
success of our planned trial. We therefore concluded
that feasibility and pilot work of cardiac rehabilitation
versus usual care (no rehabilitation) for people diag-
nosed with CRC was required.
The overall aims of the Cardiac Rehabilitation In Bowel
cancer (CRIB) study were to assess whether using cardiac
rehabilitation is a feasible and acceptable model of
rehabilitation to aid the recovery of post-treatment CRC
patients (i.e. examine intervention implementation poten-
tial) and to test the feasibility and acceptability of the
protocol design (i.e. examine methodological standard).
Thus, the purpose of the study was to assess whether it
was appropriate to progress to a larger-scale trial and, if
so, to optimise the design and conduct of any such trial.
A report of the feasibility and acceptability of the inter-
vention is reported elsewhere [15]. In this manuscript, we
describe and report data that directly addresses the
feasibility and acceptability of trial procedures. We report
screening, eligibility, consent, randomisation, adverse
event, retention, completion, missing data, and interven-
tion adherence rates. We also report reasons for exclusion,
reasons for not consenting, sample characteristics, group
(intervention versus control) characteristics, and distribu-
tion of the primary outcome. The findings of an embed-
ded qualitative study about participants’ experiences of
trial components are also reported. In this manuscript, we
do not report site-level data (the study was conducted in
three sites); however, a detailed description of site-level
recruitment performance is reported elsewhere [16]. We
also do not report effectiveness data because it is generally
recommended that feasibility and pilot studies descrip-
tively evaluate a trial’s feasibility, acceptability and safety
rather than test the effectiveness hypotheses of the
planned main large-scale trial [2, 17–19]. This is because
the small amount of effect data available in feasibility and
pilot studies means the degree of uncertainty is such that
the chance of reaching inaccurate conclusions about inter-
vention effect is high. Hence, robust and rigorous assess-
ment of an intervention’s therapeutic implications must
await adequately sized definitive pivotal trials [19].
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Methods
A full description of methods is available elsewhere [20].
A brief description is presented below.
Trial methods
(i) Participants
People with CRC were recruited from three UK hospitals.
Inclusion
– ≥18 years
– Diagnosed with primary CRC
– In recovery period following CRC surgery
(including those receiving adjuvant therapy
such as chemotherapy and radiation therapy)
Exclusion
– Advanced disease
– Failure of clinical/risk assessment for cardiac
rehabilitation
– Deemed unsafe to participate in exercise by cancer
nurses during screening
– Severe cognitive impairment
– Unable to communicate in English
(no funds available in trial for translation services)
(ii) Recruitment
A clinical nurse specialist assessed people admitted for
surgery for CRC to determine their eligibility for the
study; those eligible were given a study information
sheet. After discharge from hospital, a researcher con-
tacted people by telephone to discuss what the trial
involved. If the person was interested, and ready to
attend cardiac rehabilitation, a mutually convenient time
for the person to meet with the researcher was arranged
where eligibility was confirmed. Written consent was
obtained face to face at this initial appointment. Partici-
pants who consented had baseline measures taken and
were then randomised to either the intervention or
control group. If the person decided not to participate in
the study during the telephone call, or before giving
consent at their initial appointment, a reason for declining
was recorded by a researcher, if agreed by the individual.
(iii) Randomisation and concealment
Randomisation of individual participants to a particular
trial arm (cardiac rehabilitation (intervention arm) ver-
sus non-rehabilitation (control arm) was undertaken im-
mediately after baseline measures by a researcher using
an automated online randomisation system that was
managed by a UK-registered clinical trial unit. Hence,
randomisation was concealed from the researcher before
baseline measures but not during follow-up.
(iv) Treatment group allocation
Usual care Patients were given a booklet by Bowel Cancer
UK (a cancer charity)—‘Staying healthy after bowel cancer’.
Intervention Patients were informed they would be re-
ferred to cardiac rehabilitation. A researcher completed
a patient referral form and sent it on to the cardiac
rehabilitation service. A member of the cardiac multi-
disciplinary team (e.g. cardiac physiotherapist or nurse)
then contacted the participant and invited them to
attend a cardiac rehabilitation clinical/risk stratification
assessment to determine whether the participant was
able to safely exercise. Participants who were deemed
safe to exercise were then given a date to start cardiac
rehabilitation, which comprised exercises classes and
cardiac-specific education sessions. Participants attended
a 1-h exercise class each week over a period of 10 weeks
in site 1 and 12 weeks in site 2 and attended twice
weekly over a period of 6 weeks in site 3. Additionally,
participants were invited along to the weekly education
sessions delivered by the cardiac rehabilitation team.
Session themes across the three sites included healthy
lifestyle sessions (e.g. diet, physical activity, relaxation/
stress management) and cardiac-specific sessions (e.g.
misconceptions, medications, ‘healthy heart’).
(v) Outcomes to assess clinical- and cost-effectiveness and
data collection
Outcomes The amount of physical activity was assessed
objectively using Actigraph GT3X+ accelerometer. Partici-
pants were given an accelerometer to wear around their
waist during waking hours for seven consecutive days after
they completed other measures (e.g. quality of life ques-
tionnaires) at baseline and similarly, for seven consecutive
days after follow-up measures. There was not retrospect-
ive self-reported assessment of amount of physical activity
before participants had a colorectal cancer diagnosis. The
type of physical activity was assessed subjectively using
the Scottish Physical Activity Questionnaire (SPAQ) to as-
certain the types of activities participants engaged in [21].
Participants were asked to record the number of minutes
for each day of the week spent undertaking each type of
activity. Quality of life was assessed using the European
Quality of life 5 Dimensions (EQ-5D) [22]. The Functional
Assessment of Cancer Therapy-Colorectal (FACT-C) was
used to measure cancer-specific quality of life [23].
Anxiety and depression was measured using the Hospital
Anxiety and Depression Scale (HADS) [24]. Fatigue was
measured using the Functional Assessment of Chronic Ill-
ness Therapy-Fatigue (FACIT-Fatigue) scale, [25]. Health-
care resource use was measured using a seven-item self-
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report questionnaire developed by the research team for
the purposes for the study.
The following process variables were also collected:
physical activity self-efficacy was measured using a 12-
item questionnaire developed by investigators of the
ActWell trial [9] and designed specifically to measure
physical activity self-efficacy in the context of delivering a
behaviour change intervention. Risk perception was
measured using recommended operationalization of the
concept in the context of behaviour change research [26].
Data collection A researcher collected baseline mea-
sures immediately after the participant had provided
written consent in order to gather data before partici-
pants allocated to the intervention group began cardiac
rehabilitation. Bristol online surveys website (http://
www.survey.bris.ac.uk) was used for the self-report ques-
tionnaires. A researcher read each question out and in-
putted the participant’s response immediately using the
online system. Participants were given an accelerometer
on the same day as baseline measures were collected.
They were given a factsheet about wearing the device
and asked to wear the device for seven consecutive days
and return in the pre-paid envelope supplied to them.
The first follow-up assessment coincided with the end of
the intervention delivery period (or equivalent period for
participants allocated to the control group), that is, after
the participant had attended the final cardiac rehabilitation
class. This time scale was 10, 12, and 6 weeks for sites 1, 2,
and 3, respectively. The second follow-up assessment was
approximately 3 months after the participant had finished
cardiac rehabilitation (or equivalent period for participants
allocated to the control group). Follow-up measures were
collected at the academic institution, hospital, or partici-
pant’s own home using the same procedures used to collect
measures at baseline. The participants were requested to
wear the Actigraph GT3X+ accelerometer for seven con-
secutive days for the second time.
(vi) Outcomes to assess feasibility and acceptability of trial
parameters
Outcomes used to assess the feasibility and acceptability of
key trial parameters were screening, eligibility, consent,
randomisation, adverse events, retention, completion,
missing data, and intervention adherence rates. Reasons
for exclusion and reasons for not consenting were recorded
and data to assess sample characteristics and distribution
of the primary outcomes were also collected. Definitions
for these key trial parameters are described below.
Screening rate The screening rate was defined as the
number of people with CRC who were admitted for surgery
and assessed for eligibility by a clinical nurse specialist using
inclusion/exclusion criteria. Demographic information was
collected about all eligible patients with CRC. This included
those who subsequently decided not to take part with their
permission. Clinical trial software Open Clinica (https://
openclinica.com) was used to enter information locally at
each site allowing clinical data management for analysis.
Eligibility rate and reasons for exclusion The eligibil-
ity rate was calculated in the following two ways: (a)
dividing the number of people with CRC admitted for
surgery by the number who met inclusion criteria and
(b) dividing the number of people screened for eligibility
by the number who met inclusion criteria. Data entered
into OpenClinica were used for these calculations.
Nurses recorded their reasons for excluding patients on
a screening and recruitment form. A researcher entered
these data into OpenClinica.
Consent rate and reasons for not participating in the
study The consent rate was calculated by dividing the
number of people with CRC who met inclusion criteria
and therefore eligible for the study, by the number who
consented in writing to participate in the study using
data entered into OpenClinica. A researcher recorded
on a local site log reasons why people with CRC who
met inclusion criteria and verbally consented to having
their contact details given to the research team then
decided not to participate in the study.
Randomisation rate and group characteristics The
randomisation rate was calculated by dividing the number
of consenting participants by the number randomised to
the cardiac rehabilitation or usual care (no rehabilitation)
group. Group characteristics were compared by age, gender,
diagnosis (using the Tumour, Node, and Metastases (TNM)
classification system), type of treatment, and stoma.
Adverse events Adverse events were recorded on a local
site adverse event participant log by a researcher. Events
were recorded as ‘related’ or ‘unrelated’ to the study.
Retention rate The retention rate was defined as the
number of participants who remained in the study, that
is, the number of participants who did not formally drop
out of the study using data entered into OpenClinica.
Completion rate The completion rate was defined in
the following two ways: (a) the number of participants
who completed the self-reported questionnaires and (b)
the number of participants who returned an accelerom-
eter device that was then checked for validity by a
researcher. Completion rates were calculated at baseline,
T1, and follow-up.
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Missing data Missing data was defined as the number
of participants with invalid accelerometer data. The
validation parameters and cut-off points described below
were chosen because they have been used in cross-
sectional [27–29] and intervention studies [11] that have
measured physical activity and sedentary behaviour
among people with CRC. Actigraph software wear-time
validation was set to meet the following criteria:
 Minimum number of valid days required = 4
 Non-wear time was set at >60 min of consecutive
zeros
 Minimum number of wear hours per day required
≥10 h (600 min)
There is no international consensus about analysing
accelerometer data for people with cancer [11, 30], and
there have been only a handful of studies that used accel-
erometers to measure physical activity in people with
colorectal cancer [29]. We therefore turned to the non-
cancer literature for guidance including how the 54 differ-
ent research teams analysed the accelerometer data from
the National Health and Nutrition Examination Survey
(NHANES) [31]. Research teams applied different deci-
sions rules to analyse NHANES accelerometer data; 23
teams required a minimum of 4 days wear time, 42 teams
defined non-wear time as >60 min of consecutive zeros,
and 49 defined a valid day as 10 h or more of wear time.
Intervention adherence Intervention adherence was
measured by summing the total number of cardiac
rehabilitation exercise classes attended by participants
allocated to the intervention group. Data was collected
from the local cardiac rehabilitation register of attend-
ance by a researcher.
Sample characteristics Sample representativeness was
assessed by comparison of the characteristics of eligible
consenting and not consenting patients who gave
permission to have clinical and socio-demographic infor-
mation about them used for the purposes of the study.
Socio-demographic (e.g. age, gender) and clinical charac-
teristics (e.g. diagnosis, treatment, temporary, or per-
manent stoma) were obtained, with permission, from
nurses who had access to patient records.
Distribution of the primary outcome Recruitment bias
was assessed by examining the distribution of moderate-
to-vigorous physical activity (MVPA) measured at base-
line and second follow-up. MVPA was classed as >1951
counts per minute, as per Freedson [32] cut points in
Actigraph software. Total MVPA was chosen because
the recommended amount of physical activity for cancer
patients [33] is the same as for the general public and is
currently 150 min of moderate intensity physical activity
or 75 min of vigorous intensity activity per week (in at
least 10-min bouts) or an equivalent mix of the two [34].
(vii) Sample size
The aim of the study was not to provide a definitive
estimate of treatment effect, so we did not have a formal
sample size calculation. Rather, we estimated that we
would recruit 66 participants over the 6-month period.
This was based on the following:
– Number of surgical admissions across all three sites
in the previous year
– Cancer clinician estimates of eligibility of surgical
admissions (33 % ineligible)
– Recruitment rate from a UK trial involving physical
activity and similar clinical population (estimated
that approximately 33 % will consent) [35]
This recruitment period was fixed at 6 months, which
is reasonable for pilot and feasibility work.
(viii) Analysis
Descriptive statistics were used to summarise the screening,
eligibility, consent, randomisation, adverse events, reten-
tion, completion and missing data, intervention adherence
rates, and sample representativeness and recruitment bias.
Embedded qualitative study
All trial participants (i.e., people with CRC) provided
informed consent at baseline to be approached by a
researcher about participating in an interview. All partici-
pants were contacted by telephone and invited for inter-
view. If they were willing to be interviewed, a mutually
convenient time and place was arranged to conduct the
interview. Interviews were either at the first or second
follow-up depending on what was most convenient for
participants. Semi-structured interviews were chosen to
collect data because they allow flexibility in what sequence
questions are asked and in whether and how particular
areas might be followed up and developed with different
interviewees [36]. Questions focused on key trial parame-
ters such as experiences of randomization and participant
burden. Two investigators analysed qualitative data, one
of whom was involved in conducting the interviews and
the other was the Principal Investigator. Audio-recorded
interviews were transcribed verbatim and analysed
thematically. The Framework approach, which is a
rigorous method providing a structure within which
qualitative data are organised and coded and themes
identified, was used to guide the analysis [37].
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Ethical approval and research governance
National Health Service (NHS) ethics approval was
provided (REC reference 13/NS/0004; IRAS project ID
121757). NHS Research Management approvals (an
additional approval required in the UK for research
involving NHS patients, staff, or premises) were pro-
vided by each of the three Health Boards where the
study was conducted.
Results
Figure 1 shows the flow of participants throughout the trial.
Screening rate
The screening rate was 79 %. One hundred ninety-eight
people were admitted to the hospital for CRC surgery
across three sites and over the 6 months recruitment
period. CRC nurses assessed 156 for eligibility.
Fig. 1 Flowchart of participants
Hubbard et al. Pilot and Feasibility Studies  (2016) 2:51 Page 6 of 15
Eligibility rate and reasons for exclusion
As previously mentioned, two calculations for eligibility
were conducted. First, the eligibility rate was calculated
by dividing the number of people with CRC admitted for
surgery by the number who met inclusion criteria. No
participants who were allocated to the intervention arm
of the trial were excluded because they were deemed
unsafe to exercise by the cardiac rehabilitation team.
Hence, the eligibility rate represents the number of
screened patients who met inclusion criteria according
to the cancer clinical team. The eligibility rate was 67 %.
Out of the 198 people admitted to hospital for CRC
surgery, 133 met eligibility criteria.
Second, the eligibility rate was calculated by dividing
the number of people screened for eligibility by the
number who met inclusion criteria. The eligibility rate
was 85 %. Out of the 156 people who were screened by
nurses for eligibility, 133 met inclusion criteria.
Two out of three sites reported reasons for ineligibil-
ity. Table 1 shows that the main reason for excluding a
patient was poor mobility. Sites 1 and 2 had a total of
116 people admitted to hospital for CRC surgery and of
these, 8 (7 %) were excluded due to poor mobility and 5
(4 %) for other health reasons.
Consent rate and reasons for not participating in the study
The consent rate was 31 %. Forty-one out of 133 eligible
patients gave written consent. Thirty-three eligible
patients who did not agree to participate in the study,
however, consented to have socio-demographic and
clinical information (including reasons for declining to
participate) used for the purposes of the study. Reasons
for non-participation are presented in Table 2. The most
common reason fell into the clinical category, which
included poor recovery from surgery, co-morbidity or
receiving adjuvant therapy (15 out of 33, 46 %).
Randomisation rate
Twenty-one participants were randomised to the cardiac
rehabilitation group and 20 to the usual care (no rehabilita-
tion) group. Twenty-seven men (65.9 %) and 13 (34.1 %)
women were recruited to the study. The number of men
allocated to the cardiac rehabilitation and usual care (non-
rehabilitation) groups was 13 (61.9 %) and 14 (70 %),
respectively. The mean age of participants was 66 years (SD
11.31); the youngest participant was aged 42 years and the
oldest was aged 86 years. The mean age of participants
allocated to the cardiac rehabilitation and usual care (no re-
habilitation) groups was 67.9 (SD 11.49) and 64.2 (SD
11.10) years, respectively. There were marginal differences
between participants in the intervention and control
groups; for example, seven (33.3 %) participants allocated
to the cardiac rehabilitation group and four (20 %) allocated
to the usual care (no rehabilitation) group were classified as
T3. However, it is difficult to make direct comparisons be-
tween the two groups because of missing data. Table 4
shows nine (22 %) participants had missing information
about tumour size, 13 (31.7 %) had missing information
about lymph nodes containing cancer cells, and 36 (87.8 %)
had missing information about metastases. The most likely
explanation for missing data is that Tumour, Node and Me-
tastases (TNM) was not known at the time when diagnosis
was recorded and inputted by into OpenClinica. However,
there was no missing data about whether participants had
colon or rectal surgery, and there was a near even split be-
tween participants allocated to the cardiac rehabilitation
and usual care (no rehabilitation) groups who had colon
surgery and rectal surgery. More participants allocated to
the cardiac rehabilitation group compared to the usual care
(no rehabilitation) group had laparoscopic surgery (n = 6
(28.8 %) versus n = 3 (15 %)), whereas more participants
allocated to the cardiac rehabilitation group compared to
the usual care (no rehabilitation) group had open surgery
(n = 13 (65 %) versus n = 10 (47.6 %)). Four (19 %) partici-
pants allocated to the cardiac rehabilitation group had a
temporary stoma or permanent stoma, whereas nine (45 %)
participants allocated to the usual care (no rehabilitation)
group had a temporary stoma or permanent stoma.
Adverse event rate
No adverse events were reported in the pilot trial.
Table 1 Reasons for ineligibility (sites 1 and 2 only)
Reason given
by nurse
Number of
patients excluded
Exclusion criteria
(1 to 3)
Poor mobility 8 2
Other health reason 5 2
Advanced disease 2 1
Unable to provide consent 3 3
Patient is a full-time carer 1 N/A
Unknown 4 N/A
Total 23 –
N/A not applicable
Table 2 Reasons for declining to participate (n = 33)
Reason All sites
Distance/travel barriers 2 (6 %)
Return to normal activities 3 (9 %)
Clinical, e.g. poor recovery from surgery, co-morbidity 9 (28 %)
Other commitments/time 2 (6 %)
Adjuvant therapy 6 (18 %)
Study time limit 3 (9 %)
Unable to contact 1 (3 %)
Patient death 1 (3 %)
Missing (out of 33) 6 (18 %)
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Retention rate
The retention rate was 93 %. Three out of 41 partici-
pants formally left the study (two control and one inter-
vention). The three that left the study were from site 3.
Completion rate
The completion rate for questionnaires (SPAQ, FACT-C,
EQ-5D, FACIT-Fatigue, HADS) at baseline, follow-up 1,
and follow-up 2 was 97.5 % (20 intervention, 20 control)
75.6 % (15 intervention, 16 control), and 61 % (12 inter-
vention and 13 control), respectively.
The completion rate for accelerometers at baseline,
follow-up 1, and follow-up 2 was 68 % (14 intervention
and 14 control), 56 % (11 intervention 12 control), and
34 % (6 intervention and 8 control), respectively. There
was a total of 65 accelerometer device datasets across all
three time-points.
Missing accelerometer data
Twenty out of 65 (31 %) accelerometer device datasets
were removed from analysis because data were invalid.
Table 3 shows that the main reason for missing acceler-
ometer data was not wearing the device (35 %).
Intervention adherence
Thirteen out of 21 participants (62 %) completed the
cardiac rehabilitation programme. Three participants
started cardiac rehabilitation but could not complete all
cardiac rehabilitation classes and five did not begin
cardiac rehabilitation (38 %).
Sample characteristics
Fifty-four out of 133 eligible patients who did not consent
to participate in the study consented to have their demo-
graphic and clinical information used for the purposes of
this study. Table 4 shows that there were no significant
differences in age, gender, and type of surgery (colon or
rectal) between consenting and non-consenting eligible
patients but suggests that people with metastatic disease
(T4 and N1/N2 classification), having open surgery, and
with a stoma are more likely not to participate.
Distribution of the primary outcome
Minutes of MVPA per day was calculated by dividing the
total score by number of days worn. Table 5 shows that
participants were meeting or not far off meeting the rec-
ommended level for MVPA (i.e., 30 min a day). MVPA
per day scores were skewed towards lower scores at base-
line but normally distributed at 3-month follow-up.
Findings from the qualitative interviews
(i) Themes
Twenty-two participants (12 cardiac rehabilitation group
and 10 usual care (no rehabilitation group)) agreed to an
interview. Unsurprisingly, themes closely matched the
focus of the interview, which included questions about
trial procedures. The main theme was ‘barriers to involve-
ment in a study about cardiac rehabilitation’ with the fol-
lowing sub-themes: randomisation, study information,
and participant burden (questionnaires and accelerome-
ters). Table 6 presents participant quotations, which were
selected by the research team to illustrate each sub-theme.
(ii) Randomisation
For some participants, randomisation did not seem to be
a major barrier to study participation because they did
not mind which group they were allocated to. Neverthe-
less, some participants expressed disappointment being
allocated to the usual care (no rehabilitation) group.
Some participants were not clear how randomisation
worked and its implications. Further, the impression
given was that some participants allocated to the usual
care (no rehabilitation) group felt abandoned.
(iii) Study information
When participants were asked about study information,
most gave a perfunctory response. They either briefly
replied that the information was clear or they gave the im-
pression that they could not remember what they had
been given. Thus, although study information was not ne-
cessarily a barrier to participation, neither did it appear to
promote participation. None of the participants raised any
concerns about being approached about the study when
they were on the surgical ward, either waiting for surgery
or recovering from surgery and waiting to be discharged.
(iv) Participant burden
Some participants did not have any problems with the
questionnaire, whereas others felt it was perhaps too
long and repetitive, taking up to 35 min to complete in
some cases. Nevertheless, the overall impression given
was that the questionnaire was not a major burden for
participants to complete. Some participants commented
on the length of the questionnaire. Other participants
commented on question repetition.
Table 3 Reasons for missing accelerometer data (n = 20)
Reasons invalid Intervention
(n = 11)
Control
(n = 9)
Total
Days worn (<4) 0 3 3 (15 %)
Hours per day (<10) 2 3 5 (25 %)
Not worn at all 5 2 7 (35 %)
Abnormal activity patterns 4 1 5 (25 %)
Total 11 9 20
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Some participants reported no problems wearing the
accelerometer. Nevertheless, other participants reported
problems wearing the accelerometer. The device proved
particularly troublesome to wear for those who had a
stoma or abdominal wound problems. Some participants
appeared to be self-conscious when wearing the device.
Discussion
The success of a large-scale multi-centre pragmatic trial
of an intervention should not be judged on whether or
not the results show that an intervention is successful or
not. A biased and imprecise pragmatic trial with results
that show an intervention is effective is not a useful trial.
According to Consolidated Standards of Reporting Trials
(CONSORT) guidance, interpretation of the results (in-
ternal validity) and generalizability (external validity) of
the trial results are two key factors that can be used to
assess whether a trial is useful and hence, successful
[38]. Pilot and feasibility studies may help researchers to
predict whether any future trial is likely to be useful, and
data from pilot and feasibility studies can be used to im-
prove trial procedures to maximise the chances of any
future trial being successful.
The screening rate of potential participants can be
used to assess if those recruited to a study are likely to
be representative or typical of the target population. If a
large number of people are not screened for eligibility
then this may indicate potential recruitment bias. Only
two published studies involving physical activity inter-
vention for CRC patients have included screening rates
Table 4 Characteristics of consenting and not consenting
eligible patients
Not consenting N (%)
total N = 54
Consenting N (%)
total N = 41
Age (years)
N 54 41
Missing 0 0
Mean 65.6 66.0
SD 13.81 11.31
Median 65.5 67.0
Sex
Male 39 (72.2) 27 (65.9)
Female 15 (27.8) 14 (34.1)
Primary tumoura
Missing 13 (24.1) 9 (22.0)
T0 2 (3.7) 1 (2.4)
T1 1 (1.9) 3 (7.3)
T2 8 (14.8) 12 (29.3)
T3 20 (37.0) 11 (26.8)
T4 10 (18.5) 5 (12.2)
Regional lymph nodea
Missing 19 (35.) 13 (31.7)
Nx 1 (1.9) 0
N0 21 (38.9) 22 (53.7)
N1 13 (24.1) 6 (14.6)
Distant metastasisa
Missing 48 (88.9) 36 (87.8)
M0 5 (9.3) 5 (12.2)
M1 1 (1.9) 0
Colon surgery
Yes 33 (61.1) 25 (61)
No 21 (38.9) 16 (39)
Rectal surgery
Yes 19 (35.2) 16 (39)
No 35 (64.8) 25 (61)
Laparoscopic surgery
Missing 1 (1.9) 0 (0)
No 37 (68.5) 32 (78)
Yes 16 (29.6) 9 (22)
Open surgery
Missing 1 (1.9) 0
No 21 (38.9) 18 (43.9)
Yes 32 (59.3) 23 (56.1)
Temporary stoma
Missing 3 (5.6) 0
No 39 (72.2) 35 (85.4)
Yes 12 (22.2) 6 (14.6)
Table 4 Characteristics of consenting and not consenting
eligible patients (Continued)
Permanent stoma
Missing 3 (5.6) 0 (0)
No 45 (79.6) 34 (82.9)
Yes 8 (14.8) 7 (17.1)
Chemotherapy
Missing 11 (20.4) 7 (17.1)
No 37 (68.5) 27 (65.9)
Yes 6 (11.1) 7 (17.1)
Radiotherapy
Missing 10 (18.5 %) 7 (17.1)
No 36 (66.7 %) 29 (70.7)
Yes 8 (14.8 %) 5 (12.2)
Other treatment
Missing 4 (7.4 %) 3 (7.3)
No 49 (90.7 %) 35 (85.4)
Yes 1 (1.9 %) 3 (7.3)
aTNM stands for Tumour, Node, and Metastases. This staging system describes
the size of a primary tumour (T), whether any lymph nodes contain cancer
cells (N), and whether the cancer has spread to another part of the body (M)
Hubbard et al. Pilot and Feasibility Studies  (2016) 2:51 Page 9 of 15
[11, 14]. In the CRIB study, the majority of the target
population were screened. Thus, based on the screening
rate of the CRIB study, we can estimate that participants
in a future large-scale will be typical of the target
population.
Another indicator that can be used to assess if partici-
pants are representative of the target population and
therefore how confident we can be in generalising study
results to the target population is by comparing the
characteristics of eligible consenting and not consenting
patients. In the CRIB study, we found that there were no
meaningful differences in age, gender, and type of
surgery (colon or rectal) between consenting and non-
consenting eligible patients but people with metastatic
disease (T4 and N1 classification), having open surgery,
and with a stoma, were more likely not to consent. Our
qualitative study highlighted that a stoma was problem-
atic for some participants. Additionally, people with a
stoma may be embarrassed [16]. Future trials of struc-
tured physical activity interventions should therefore
consider ways of addressing problems of participation
associated with a stoma. Moreover, if a sample is to be
representative and typical of the target population then
strategies to support people who have had open surgery
to participate in a structured physical activity interven-
tion or are living with metastatic disease may need to be
implemented.
Examining the distribution of participants on out-
comes can be used to assess potential recruitment bias.
In the CRIB study, at baseline, most participants were
averaging 30 min of MVPA a day and therefore meeting
Table 5 Minutes per day of MVPA
Variable Intervention Control Total
Sum of moderate–vigorous time (minutes per day)
N 14 14 28
Missing 0 0 0
Mean 21.1 29.0 25.1
SD 11.68 35.90 26.50
95 % LCL 14.40 8.27 14.80
95 % UCL 27.89 49.72 35.34
Median 20.6 10.5 17.8
Sum of moderate–vigorous time (minutes per day)
3-month follow-up
N 6 8 14
Missing 0 0 0
Mean 22.5 54.5 40.8
SD 17.41 28.34 28.63
95 % LCL 4.27 30.85 24.30
95 % UCL 40.81 78.24 57.36
Median 23.9 56.3 35.6
3-months follow-up minus baseline
N 6 7 13
Missing 0 0 0
Mean 1.3 10.5 6.2
SD 15.04 28.37 22.79
95 % LCL −14.51 −15.74 −7.53
95 % UCL 17.06 36.73 20.01
Median 0.3 7.7 4.2
Table 6 Participant quotations for each sub-theme
Sub-themes Quotationsa
Randomisation “Fine, I had no feelings one way or another
[about being allocated to cardiac rehabilitation
or usual care (no rehabilitation) group].
I was quite happy to participate one way
or t’other.” (site 1 23 usual care)
Investigator: Were you a little bit disappointed
[not being allocated to the cardiac
rehabilitation group]?
Participant: I was because I thought the
exercise might help me.” (site 2 09 usual care)
Study information “I got a big form with more information but I
haven’t read it [laughs].” (site 2 17 usual care)
Investigator: “Do you feel that all the information
you were given was clear?
Participant: Yes I’m sure it was…
I can’t remember reading the booklet.
I think it was just verbal but maybe I should
have read the booklet [laughs].”
(site 2 09 usual care)
Investigator: “Was it an appropriate time to
discuss the study?
Participant: Yeah.
Investigator: There was nothing inappropriate
about the timing or insensitive?
Participant: Not for me anyway.”
(site 2 17 usual care)
Participant burden:
questionnaires
“Oh they’re fair, the questions are fair, yes, and
eh, I mean, there’s nothing that I’m stumbling
to answer, you know, it’s very simple and eh
straightforward.” (site 1 02 cardiac rehabilitation)
“I think they’re quite long.”
(site 1 13 cardiac rehabilitation)
“A wee bit long, a wee bit long, I'm saying eh,
and, no, eh aye seemed tae be getting the same
question, again and again.”
(site 2 02 cardiac rehabilitation)
Participant burden:
accelerometers
“Easy to use. I think I wore it quite diligently.”
(site 1 19 usual care)
“I realised you had to do it [wear accelerometer]
but I was putting up with so much with stitches
round my rear end, stitches from here to there
like top to bottom on my front, plus the [stoma]
bag and all the rest.” (site 3 02 usual care)
aIdentifiers are the site (1 to 3), unique participant number and whether the
participant was allocated to the cardiac rehabilitation or usual care (no
rehabilitation) group
Hubbard et al. Pilot and Feasibility Studies  (2016) 2:51 Page 10 of 15
the recommended guidelines for physical activity for
cancer patients [33] and the general population [34].
However, studies have shown that most CRC patients
[39–42] and members of the general population [43] are
not meeting these targets. Thus, in the CRIB study, there
was recruitment bias in favour of physically active CRC
patients. This has important implications for those who
are making decisions about treatment options because
there seems little clinical value in providing a service to
these patients because they are likely to be obtaining
health benefits associated with post-diagnosis physical
activity (unless of course, there is a dose effect for phys-
ical activity and the intervention is designed to support
people already meeting recommended guidelines be-
come even more active). Given that most patients in the
CRIB study were physically active, it is likely that extra
efforts will have to be made to recruit people who are
less active. Introducing motivational strategies, such as
providing information about the benefits of being active,
may help recruitment because according to behavioural
change theory, internalisation of the value (the benefits)
of the outcomes of physical activity is likely to lead to
greater persistence in being physically active [44]. More-
over, other studies have excluded people with CRC who
are already meeting recommended guidelines for
physical activity, suggesting that it is possible to recruit
inactive CRC patients [6, 11].
Eligibility rates can be used to assess if those recruited
to a study are likely to be representative of a target
population and thereby the generalizability of the study.
If most of the total population are eligible, then we can
conclude that the study is highly representative of the
target population. In the CRIB study, the eligibility rate
was 67 %. However, most studies of structured physical
activity interventions with the exception of Lee et al.
(2013) [14] and Pinto et al. (2013) [11] do not report the
total population from which the sample was drawn and
calculate the eligibility rate as the proportion of screened
patients who met inclusion criteria [3–14]. The problem
with this approach however is that there is no way of
knowing how many patients were excluded from the
study because they were not screened. Future studies
should therefore consider reporting the total population
and the screening rate.
In pragmatic trials, where the aim is to assist decision
makers about treatment options, the principle of equit-
able healthcare [45] is likely to be taken into consider-
ation and should therefore be examined in feasibility
and pilot studies. Poor mobility and other health prob-
lems were the most common reasons nurses gave for
excluding patients in the CRIB study. Yet, some people
with poor mobility and health problems may benefit
from a structured physical activity intervention and
should therefore be included. The CHALLENGE trial
has recently reported that staff did not approach people
who ‘do not look like an exerciser’ [46]. Hence, research
teams should make an effort to ensure that all staff de-
fine eligibility criteria appropriately. If exclusion from
trials is a proxy for exclusion from interventions should
they be implemented as part of routine healthcare, then
the principle of equitable healthcare seems therefore at
risk for structured physical activity interventions for
CRC patients. Induction and training of recruiters about
the benefits of physical activity and contraindications for
exercise may therefore be particularly important to
ensure that structured physical activity studies and inter-
ventions, if implemented, are equitable. Yet, studies also
need to make sure that participants are safe to exercise.
Some studies (including the CRIB study) relied on clin-
ician judgement to decide if it was safe for a patient to
exercise [11, 13], and other studies used forms of assess-
ment such as fitness tests [12, 14] or disease indices [7].
Adverse events are also an indicator of safety. In the
CRIB pilot trial, no adverse events were reported.
The randomization process can lead to potential bias
if methods used to allocate participants to the different
arms of the trial do not create a situation where partici-
pants have a 50:50 chance of being allocated to one
group or the other. In the CRIB study, an electronic
random allocation sequence generator managed by a
registered UK clinical trial unit was used thereby making
it unlikely that the randomisation process was biased. In
the CRIB study, we compared the characteristics of par-
ticipants allocated to the two arms of the trial to assess
for any bias. Missing data about diagnosis meant that we
were not able to make all comparisons but there were
differences between groups on some variables, such as
more patients in the usual care (no rehabilitation) group
having a stoma. These differences may impact on out-
comes, and therefore, it is important that these data are
reported. Moreover, while allocation to the two arms of
the trial was concealed from the researcher before base-
line measures, it was not concealed during follow-up
measures, which could introduce bias..
To facilitate interpretation of the results of a trial,
CONSORT guidelines recommend understanding factors
that suggest potential imprecision [38]. A low consent
rate could indicate potential imprecision because a study
may be underpowered. Underpowered studies limit the
ability to draw conclusions about the effect of an inter-
vention on health outcomes and are more likely to go
unpublished or report statistically non-significant results.
Poor recruitment for physical activity interventions
increases the chance of the trial being abandoned, with
potentially important clinical effects of that intervention
not getting shared or reported [43–45]. The CRIB
study’s consent rate was 31 %, which is higher than some
studies that report 10 % [6] and 12 % [14] but lower than
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other studies that report 78 % [13] and 70 % [11] consent
rates. Understanding reasons for non-participation is
therefore important because this information can be used
to improve consent rates in future studies and, in turn,
minimise one of the threats to precision of a trial. How-
ever, in the CRIB study, only 33 of eligible participants
who did not consent to participate in the study agreed to
give a reason why they did not wish to participate and
twice as many (n = 65) did not agree to give a reason. This
may be because researchers did not clearly explain the im-
portance to research of collecting such information. In the
CRIB study and other studies of structured physical activ-
ity interventions for CRC patients, ‘medical conditions’
and ‘not interested’ are the most common reasons given
for eligible participants not consenting [3, 5, 11–14].
These factors may also explain why CRC patients drop
out of intervention trials. Studies promoting change in
diet and physical activity in individuals with a diagnosis of
colorectal cancer reported health concerns, personal rea-
sons, and inability to commit as reasons for participant
drop-out [47]. Encouraging eligible people to participate
in a physical activity trial however will be challenging and
strategies to motivate this group to participate in a clinical
trial and maintain engagement in physical activity inter-
ventions should be developed. Strategies are likely to com-
prise those that are relevant to clinical trial participation
in general such as improving communication between cli-
nicians and patients with cancer about research [48] as
well as strategies that directly address barriers to physical
activity participation in people with CRC such as fatigue
[49].
Another trial parameter that indicates potential impre-
cision is loss of participants to a study, which may be
due to a combination of factors, including participants
formally dropping out of the study (retention rate), fail-
ing to complete outcome measures (completion rate), or
failing to provide valid data (missing data). Loss of par-
ticipants during trial follow-up can introduce bias and
reduce power, thereby affecting the generalisability, val-
idity and reliability of results [50]. Thus, information
about retention and completion rates and missing data
is important for assessing potential bias and imprecision.
It has been estimated that a 20 % loss can threaten trial
validity [51]. Some missing data can be dealt with statis-
tically and therefore may be regarded as less of a prob-
lem than poor retention and completion; nevertheless,
the risk of bias and imprecision due to missing data can
remain [52] and therefore should be reported alongside
other rates. Retention was excellent in the CRIB study,
but the pilot trial suggests that completion rates com-
pared to other similar studies were below par. The self-
report questionnaire completion rate at second follow-
up in the CRIB study was 61 %, compared to, for
example, 78.5 % [13] and 88 % [11] completion rates in
other studies of structured physical activity interventions
for CRC patients. Our qualitative study suggests that
participant burden is a factor and that lengthy or repeti-
tive questionnaires may impact completion rates. A
recent systematic review of 38 randomised retention tri-
als evaluating six broad types of strategies to increase
questionnaire response and retention in randomised
trials concluded that no strategy had a clear impact on
increasing the number of participants returning to sites
for follow-up but found that the following strategies may
improve questionnaire response: addition of monetary
incentives for return of postal questionnaires, recorded
delivery of questionnaires, and a ‘package’ of postal com-
munication strategies with reminder letters [53]. The
qualitative interviews also highlighted that some partici-
pants allocated to the control group felt abandoned,
which may also have influenced completion rates [54].
Further research about the impact of strategies to reduce
loss of participants to a study is therefore required.
Our primary outcome was objective measurement of
physical activity using accelerometer. Hence, completion
and missing data rates for this endpoint is of particular
concern. Objective measures of physical activity have
been increasingly used to overcome limitations of self-
report measures. Research conducted among the general
population suggests that self-reported measures of phys-
ical activity are inaccurate when compared with objective
measurement from devices such as accelerometers [55–
57]. Despite the advantages of obtaining an objective
measure of physical activity, there are few guidelines for
using accelerometers in research [58, 59] and little guid-
ance on improving participant compliance [60]. Strategies
to optimise completion rates and analyses of accelerom-
eter data include the use of log sheets for participants to
record dates/times that the device is worn, wear-time al-
gorithms, and use of ‘conventional’ cutpoints and number
of hours and days to determine [61]. Nonetheless, as a re-
cent review of literature about accelerometers concluded,
questions still remain about their validity [62]. In the
CRIB study, completion rates fell from 68 % at baseline to
34 % at second follow-up. In addition, 31 % of accelerom-
eter datasets were invalid, and this was mainly because
participants did not wear the device. As our qualitative
study shows, wearing the accelerometer may be bother-
some for patients who have a stoma or wounds from
surgery and these factors should be taken into consider-
ation when selecting instruments to measure outcomes.
Recommended approaches for improving compliance
include a daily monitoring log filled out by participants,
reminder phone calls, adequate education about the
monitor and its proper wear, and identification of poten-
tial barriers to wearing with each participant [63]. These
strategies should be tested in studies of a similar context
involving CRC patients.
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A critical component to the success of physical activity
intervention trials is achieving high levels of adherence
(i.e. the extent to which the intervention group performs
the physical activity prescription). This is primarily
because adherence is related to a trial’s health outcomes
[64, 65]. Moreover, low adherence increases the risk of
policy and service commissioners rejecting interventions
that may actually be effective if adherence levels were
optimal. Addressing adherence barriers is therefore
crucial. In the CRIB study, 62 % of participants rando-
mised to the intervention group completed cardiac
rehabilitation and the main reason for either not starting
cardiac rehabilitation or stopping was poor physical
health. Other studies have reported 90 % [6] and 72 %
[13] adherence rates, suggesting that it is possible to
achieve high rates of adherence than the CRIB study
achieved with this clinical population. Nevertheless, our
adherence rates may be more realistic of adherence
levels under NHS conditions and therefore possibly of
more interest and use for service commissioners. Indeed,
one of the strengths of pragmatic as opposed to explana-
tory trials is that it is more likely to mirror what would
happen in normal practice [38].
Limitations This pilot trial was conducted in only three
sites and recruited only 41 patients, out of a predicted
66 based on surgical admissions. A note of caution is
therefore required when using these study data for esti-
mating recruitment rates etc. for any future large-scale
multi-centre trial. Some data were missing, thereby mak-
ing it difficult to accurately assess potential bias, impre-
cision, and generalizability. There is also further work
needed for measuring physical activity accurately in clin-
ical populations. Measuring sedentary time accurately
and avoiding confusion with non-wear time is a consid-
eration with the current methods. Nevertheless, the
study highlights where threats to internal and external
validity are likely to arise in any future studies of
comparable structured physical activity interventions for
colorectal cancer patients using methods being con-
ducted in similar contexts.
Conclusions
Feasibility and pilot studies are useful in highlighting
where potential threats to the internal and external valid-
ity of a large-scale multi-centre are likely to occur. Thus,
key trial parameters should be precisely described in a
pilot study and should include screening rate, eligibility
rate and reasons for exclusion, consent rate and reasons
for not consenting, randomization procedure and a com-
parison of intervention and control group characteristics,
adverse events, retention rates, completion rate, missing
data, sample characteristics, distribution of the primary
outcomes, and intervention adherence. The CRIB study
suggests that there is likely to be potential recruitment
bias in this clinical population. There is also likely to be
potential imprecision due to sub-optimal completion of
outcome measures, missing data, and sub-optimal inter-
vention adherence. Hence, strategies to manage these risks
should be developed to stack the odds in favour of
conducting a useful multi-centre trial. These findings are
applicable to interventions of similar methodology, and in
comparable clinical populations.
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